Enanta Pharmaceuticals
ENTA
NASDAQ
IPO2013
about ENTA
Enanta Pharmaceuticals develops innovative medicines to treat viral infections, including treatments for hepatitis C and COVID-19.
| type | open | high | low |
market cap |
volume |
|---|---|---|---|---|---|
| stock | $7.15 | $15.34 | $7.05 | $168.89M | 16.55M |
| eps |
price to earnings |
price to sales |
operating margin |
profit margin |
yield |
| -$1.06 | n/a | 21.06 | -164.32% | -151.71% | 0% |